China-based gene delivery technology developer VectorBuilder has entered into a partnership with Zhejiang Dapu Biotechnology Co., Ltd, a specialist in droplet microfluidics and molecular diagnostics. The collaboration aims to integrate the respective technology advantages and platform resources of both companies to overcome technological bottlenecks in life sciences and innovative biopharmaceutical research and development. The partnership also seeks to expand the global market layout and promote the technological progress and innovative development of biotechnology. Financial details of the agreement were not disclosed.
Focus on Single B Cell Antibody Screening Technology Platform
The initial focus of the partnership will be the co-development of a single B cell antibody screening technology platform. This initiative aligns with the companies’ commitment to advancing biotechnological solutions and enhancing the efficiency and effectiveness of antibody discovery and development processes.
Expanding Technological Progress and Innovation in Biotech
The partnership between VectorBuilder and Zhejiang Dapu Biotechnology Co., Ltd is expected to contribute significantly to the field of biotechnology. By combining their expertise and resources, the companies aim to drive innovation, improve research outcomes, and ultimately, enhance the global competitiveness of their technologies and products.-Fineline Info & Tech
